25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Abcellera BiologicsĀ Inc
Buy, Hold or Sell?

Let's analyze Abcellera together

I guess you are interested in Abcellera BiologicsĀ Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Abcellera BiologicsĀ Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Abcellera BiologicsĀ Inc

I send you an email if I find something interesting about Abcellera BiologicsĀ Inc.

1. Quick Overview

1.1. Quick analysis of Abcellera (30 sec.)










1.2. What can you expect buying and holding a share of Abcellera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.65
Expected worth in 1 year
$3.30
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-0.35
Return On Investment
-12.4%

For what price can you sell your share?

Current Price per Share
$2.85
Expected price per share
$2.43 - $3.58
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Abcellera (5 min.)




Live pricePrice per Share (EOD)
$2.85
Intrinsic Value Per Share
$-6.04 - $-7.23
Total Value Per Share
$-2.39 - $-3.58

2.2. Growth of Abcellera (5 min.)




Is Abcellera growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$1.2b-$28.3m-2.4%

How much money is Abcellera making?

Current yearPrevious yearGrowGrow %
Making money-$43.9m-$32.2m-$11.6m-26.5%
Net Profit Margin-552.8%-301.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Abcellera (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#65 / 949

Most Revenue
#302 / 949

Most Profit
#818 / 949

Most Efficient
#637 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Abcellera?

Welcome investor! Abcellera's management wants to use your money to grow the business. In return you get a share of Abcellera.

First you should know what it really means to hold a share of Abcellera. And how you can make/lose money.

Speculation

The Price per Share of Abcellera is $2.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abcellera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abcellera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.65. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abcellera.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-6.1%-0.15-5.2%-0.11-3.8%0.020.7%0.020.7%
Usd Book Value Change Per Share-0.53-18.7%-0.09-3.1%0.010.4%0.186.4%0.186.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.53-18.7%-0.09-3.1%0.010.4%0.186.4%0.186.4%
Usd Price Per Share2.60-3.95-7.18-10.27-10.27-
Price to Earnings Ratio-3.76--6.71--16.60--43.78--43.78-
Price-to-Total Gains Ratio-4.89--52.22--73.87--42.31--42.31-
Price to Book Ratio0.71-0.99-1.75-3.13-3.13-
Price-to-Total Gains Ratio-4.89--52.22--73.87--42.31--42.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.85
Number of shares350
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.090.18
Usd Total Gains Per Share-0.090.18
Gains per Quarter (350 shares)-31.0163.88
Gains per Year (350 shares)-124.04255.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-124-1340256246
20-248-2580511502
30-372-3820767758
40-496-506010221014
50-620-630012781270
60-744-754015331526
70-868-878017891782
80-992-1002020442038
90-1116-1126023002294
100-1240-1250025552550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%6.014.00.030.0%6.014.00.030.0%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%10.09.01.050.0%10.09.01.050.0%10.09.01.050.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%10.09.01.050.0%10.09.01.050.0%10.09.01.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Abcellera BiologicsĀ Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.532-0.089-83%0.011-4732%0.183-391%0.183-391%
Book Value Per Share--3.6503.983-8%4.079-11%3.026+21%3.026+21%
Current Ratio--9.3368.847+6%8.834+6%8.394+11%8.394+11%
Debt To Asset Ratio--0.2260.182+24%0.208+8%0.250-10%0.250-10%
Debt To Equity Ratio--0.2920.235+24%0.263+11%0.361-19%0.361-19%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1096356641.6001609611263.200-32%2620394159.920-58%4421669014.346-75%4421669014.346-75%
Eps---0.173-0.149-14%-0.109-37%0.021-940%0.021-940%
Ev To Ebitda Ratio---5.283-7.492+42%-57.266+984%-28.180+433%-28.180+433%
Ev To Sales Ratio--42.12248.333-13%56.243-25%52.894-20%52.894-20%
Free Cash Flow Per Share---0.160-0.166+4%-0.058-64%0.019-951%0.019-951%
Free Cash Flow To Equity Per Share---0.150-0.156+4%-0.052-65%0.129-216%0.129-216%
Gross Profit Margin--1.0611.074-1%1.108-4%1.112-5%1.112-5%
Intrinsic Value_10Y_max---7.228--------
Intrinsic Value_10Y_min---6.040--------
Intrinsic Value_1Y_max---0.202--------
Intrinsic Value_1Y_min---0.198--------
Intrinsic Value_3Y_max---1.006--------
Intrinsic Value_3Y_min---0.952--------
Intrinsic Value_5Y_max---2.289--------
Intrinsic Value_5Y_min---2.090--------
Market Cap841793145.600+9%767951641.6001166695763.200-34%2121466409.920-64%3143229461.477-76%3143229461.477-76%
Net Profit Margin---7.854-5.528-30%-3.012-62%-1.828-77%-1.828-77%
Operating Margin---13.858-9.927-28%-4.816-65%-3.016-78%-3.016-78%
Operating Ratio--21.27912.594+69%7.357+189%4.651+358%4.651+358%
Pb Ratio0.781+9%0.7120.991-28%1.754-59%3.125-77%3.125-77%
Pe Ratio-4.118-10%-3.757-6.714+79%-16.600+342%-43.782+1065%-43.782+1065%
Price Per Share2.850+9%2.6003.950-34%7.183-64%10.268-75%10.268-75%
Price To Free Cash Flow Ratio-4.440-10%-4.051-6.488+60%-12.679+213%-722.347+17733%-722.347+17733%
Price To Total Gains Ratio-5.360-10%-4.890-52.219+968%-73.866+1411%-42.307+765%-42.307+765%
Quick Ratio--15.36914.714+4%13.826+11%16.028-4%16.028-4%
Return On Assets---0.037-0.031-17%-0.021-42%0.001-5359%0.001-5359%
Return On Equity---0.047-0.039-17%-0.027-43%-0.010-79%-0.010-79%
Total Gains Per Share---0.532-0.089-83%0.011-4732%0.183-391%0.183-391%
Usd Book Value--1078094000.0001176514500.000-8%1204844750.000-11%908041417.450+19%908041417.450+19%
Usd Book Value Change Per Share---0.532-0.089-83%0.011-4732%0.183-391%0.183-391%
Usd Book Value Per Share--3.6503.983-8%4.079-11%3.026+21%3.026+21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1096356641.6001609611263.200-32%2620394159.920-58%4421669014.346-75%4421669014.346-75%
Usd Eps---0.173-0.149-14%-0.109-37%0.021-940%0.021-940%
Usd Free Cash Flow---47398000.000-49135908.000+4%-17190000.000-64%5741974.200-925%5741974.200-925%
Usd Free Cash Flow Per Share---0.160-0.166+4%-0.058-64%0.019-951%0.019-951%
Usd Free Cash Flow To Equity Per Share---0.150-0.156+4%-0.052-65%0.129-216%0.129-216%
Usd Market Cap841793145.600+9%767951641.6001166695763.200-34%2121466409.920-64%3143229461.477-76%3143229461.477-76%
Usd Price Per Share2.850+9%2.6003.950-34%7.183-64%10.268-75%10.268-75%
Usd Profit---51107000.000-43949250.000-14%-32285250.000-37%7710778.400-763%7710778.400-763%
Usd Revenue--6507000.0008240750.000-21%12598000.000-48%57940833.600-89%57940833.600-89%
Usd Total Gains Per Share---0.532-0.089-83%0.011-4732%0.183-391%0.183-391%
 EOD+5 -3MRQTTM+11 -27YOY+6 -325Y+10 -2810Y+10 -28

3.3 Fundamental Score

Let's check the fundamental score of Abcellera BiologicsĀ Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.118
Price to Book Ratio (EOD)Between0-10.781
Net Profit Margin (MRQ)Greater than0-7.854
Operating Margin (MRQ)Greater than0-13.858
Quick Ratio (MRQ)Greater than115.369
Current Ratio (MRQ)Greater than19.336
Debt to Asset Ratio (MRQ)Less than10.226
Debt to Equity Ratio (MRQ)Less than10.292
Return on Equity (MRQ)Greater than0.15-0.047
Return on Assets (MRQ)Greater than0.05-0.037
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Abcellera BiologicsĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.110
Ma 20Greater thanMa 502.840
Ma 50Greater thanMa 1002.736
Ma 100Greater thanMa 2002.741
OpenGreater thanClose2.850
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Abcellera BiologicsĀ Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2024-12-05 11:11:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Abcellera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • A Net Profit Margin of -785.4%Ā means thatĀ $-7.85 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abcellera BiologicsĀ Inc:

  • The MRQ is -785.4%. The company is making a huge loss. -2
  • The TTM is -552.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-785.4%TTM-552.8%-232.6%
TTM-552.8%YOY-301.2%-251.6%
TTM-552.8%5Y-182.8%-370.0%
5Y-182.8%10Y-182.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-785.4%-108.0%-677.4%
TTM-552.8%-218.6%-334.2%
YOY-301.2%-210.1%-91.1%
5Y-182.8%-339.1%+156.3%
10Y-182.8%-464.5%+281.7%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Abcellera is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • -3.7% Return on Assets means thatĀ Abcellera generatedĀ $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abcellera BiologicsĀ Inc:

  • The MRQ is -3.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.7%TTM-3.1%-0.6%
TTM-3.1%YOY-2.1%-0.9%
TTM-3.1%5Y0.1%-3.1%
5Y0.1%10Y0.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.7%-11.3%+7.6%
TTM-3.1%-11.8%+8.7%
YOY-2.1%-11.3%+9.2%
5Y0.1%-12.6%+12.7%
10Y0.1%-14.2%+14.3%
4.3.1.3. Return on Equity

Shows how efficient Abcellera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • -4.7% Return on Equity means Abcellera generated $-0.05Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abcellera BiologicsĀ Inc:

  • The MRQ is -4.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.7%TTM-3.9%-0.8%
TTM-3.9%YOY-2.7%-1.3%
TTM-3.9%5Y-1.0%-2.9%
5Y-1.0%10Y-1.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.7%-14.2%+9.5%
TTM-3.9%-15.9%+12.0%
YOY-2.7%-14.4%+11.7%
5Y-1.0%-18.5%+17.5%
10Y-1.0%-19.5%+18.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Abcellera BiologicsĀ Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Abcellera is operatingĀ .

  • Measures how much profit Abcellera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • An Operating Margin of -1,385.8%Ā means the company generated $-13.86 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abcellera BiologicsĀ Inc:

  • The MRQ is -1,385.8%. The company is operating very inefficient. -2
  • The TTM is -992.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,385.8%TTM-992.7%-393.1%
TTM-992.7%YOY-481.6%-511.1%
TTM-992.7%5Y-301.6%-691.1%
5Y-301.6%10Y-301.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,385.8%-204.6%-1,181.2%
TTM-992.7%-313.2%-679.5%
YOY-481.6%-219.0%-262.6%
5Y-301.6%-388.9%+87.3%
10Y-301.6%-495.6%+194.0%
4.3.2.2. Operating Ratio

Measures how efficient Abcellera is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Biotechnology industry mean).
  • An Operation Ratio of 21.28 means that the operating costs are $21.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Abcellera BiologicsĀ Inc:

  • The MRQ is 21.279. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.594. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ21.279TTM12.594+8.685
TTM12.594YOY7.357+5.237
TTM12.5945Y4.651+7.943
5Y4.65110Y4.6510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.2792.340+18.939
TTM12.5943.187+9.407
YOY7.3573.282+4.075
5Y4.6514.814-0.163
10Y4.6516.494-1.843
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Abcellera BiologicsĀ Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Abcellera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Biotechnology industry mean).
  • A Current Ratio of 9.34Ā means the company has $9.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Abcellera BiologicsĀ Inc:

  • The MRQ is 9.336. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.847. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.336TTM8.847+0.490
TTM8.847YOY8.834+0.013
TTM8.8475Y8.394+0.453
5Y8.39410Y8.3940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3363.645+5.691
TTM8.8473.883+4.964
YOY8.8344.666+4.168
5Y8.3945.964+2.430
10Y8.3946.265+2.129
4.4.3.2. Quick Ratio

Measures if Abcellera is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • A Quick Ratio of 15.37Ā means the company can pay off $15.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abcellera BiologicsĀ Inc:

  • The MRQ is 15.369. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.714. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.369TTM14.714+0.655
TTM14.714YOY13.826+0.888
TTM14.7145Y16.028-1.314
5Y16.02810Y16.0280.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.3693.014+12.355
TTM14.7143.418+11.296
YOY13.8264.456+9.370
5Y16.0285.970+10.058
10Y16.0286.424+9.604
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Abcellera BiologicsĀ Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of AbcelleraĀ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Abcellera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23Ā means that Abcellera assets areĀ financed with 22.6% credit (debt) and the remaining percentage (100% - 22.6%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Abcellera BiologicsĀ Inc:

  • The MRQ is 0.226. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.182. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.182+0.044
TTM0.182YOY0.208-0.026
TTM0.1825Y0.250-0.068
5Y0.25010Y0.2500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2260.350-0.124
TTM0.1820.341-0.159
YOY0.2080.310-0.102
5Y0.2500.365-0.115
10Y0.2500.382-0.132
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Abcellera is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • A Debt to Equity ratio of 29.2% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abcellera BiologicsĀ Inc:

  • The MRQ is 0.292. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.235. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.292TTM0.235+0.057
TTM0.235YOY0.263-0.029
TTM0.2355Y0.361-0.126
5Y0.36110Y0.3610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2920.394-0.102
TTM0.2350.432-0.197
YOY0.2630.380-0.117
5Y0.3610.451-0.090
10Y0.3610.490-0.129
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Abcellera generates.

  • Above 15 is considered overpriced butĀ always compareĀ Abcellera to theĀ Biotechnology industry mean.
  • A PE ratio of -3.76 means the investor is paying $-3.76Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abcellera BiologicsĀ Inc:

  • The EOD is -4.118. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.757. Based on the earnings, the company is expensive. -2
  • The TTM is -6.714. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.118MRQ-3.757-0.361
MRQ-3.757TTM-6.714+2.957
TTM-6.714YOY-16.600+9.887
TTM-6.7145Y-43.782+37.068
5Y-43.78210Y-43.7820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.118-2.315-1.803
MRQ-3.757-2.491-1.266
TTM-6.714-3.156-3.558
YOY-16.600-3.274-13.326
5Y-43.782-6.037-37.745
10Y-43.782-6.785-36.997
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abcellera BiologicsĀ Inc:

  • The EOD is -4.440. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.051. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.488. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.440MRQ-4.051-0.389
MRQ-4.051TTM-6.488+2.438
TTM-6.488YOY-12.679+6.190
TTM-6.4885Y-722.347+715.859
5Y-722.34710Y-722.3470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.440-2.985-1.455
MRQ-4.051-3.361-0.690
TTM-6.488-3.734-2.754
YOY-12.679-4.557-8.122
5Y-722.347-8.327-714.020
10Y-722.347-9.311-713.036
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Abcellera is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.71 means the investor is paying $0.71Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Abcellera BiologicsĀ Inc:

  • The EOD is 0.781. Based on the equity, the company is cheap. +2
  • The MRQ is 0.712. Based on the equity, the company is cheap. +2
  • The TTM is 0.991. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.781MRQ0.712+0.068
MRQ0.712TTM0.991-0.278
TTM0.991YOY1.754-0.763
TTM0.9915Y3.125-2.135
5Y3.12510Y3.1250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7811.919-1.138
MRQ0.7122.051-1.339
TTM0.9912.374-1.383
YOY1.7542.454-0.700
5Y3.1253.737-0.612
10Y3.1254.378-1.253
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Abcellera BiologicsĀ Inc.

4.8.1. Institutions holding Abcellera BiologicsĀ Inc

Institutions are holding 39.767% of the shares of Abcellera BiologicsĀ Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Baker Bros Advisors LP9.31920.74172752564000
2024-09-30Baillie Gifford & Co Limited.4.36570.025112894703-9016311-41.1497
2024-09-30ING Investment Management LLC3.5970.028610624185-8275-0.0778
2024-09-30Prosight Management, LP3.0745.809490795396726906285.931
2024-09-30UBS Asset Mgmt Americas Inc1.5540.00314590103-8523-0.1853
2024-09-30Orbimed Advisors, LLC1.41550.1975418076800
2024-09-30ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.38980.1367410509500
2024-06-30BlackRock Inc1.28770.00033803477-97087-2.4891
2024-09-30Renaissance Technologies Corp0.99760.01152946703121810070.4673
2024-09-30Two Sigma Investments LLC0.85780.0144253363547227922.9111
2024-09-30TANG CAPITAL MANAGEMENT LLC0.77870.427223000001838301398.1601
2024-09-30Federated Hermes Inc0.77280.0132282696-443320-16.2626
2024-09-30Two Sigma Advisers, LLC0.73730.0133217760041280023.3908
2024-09-30Guardian Capital Advisors LP0.60480.4522178641400
2024-09-30Citadel Advisors Llc0.50770.00081499640264301.794
2024-09-30Novo A/S0.38150.1455112691500
2024-09-30Lazard Asset Management LLC0.37130.0038109657544060.4034
2024-06-30NORGES BANK0.31220.000492221400
2024-09-30Opaleye Management Inc0.27090.3469800000600000300
2024-09-30Millennium Management LLC0.25520.000975388730319767.274
Total 32.85078.372397029789+2028903+2.1%

4.9.2. Funds holding Abcellera BiologicsĀ Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Allianz Global Artfcl Intlgc W EUR2.06630.22696103119-77588-1.2553
2024-10-31Baillie Gifford Positive Change B Acc1.62290.55074793590321350.6749
2024-10-31Baillie Gifford Positive Change1.60880.552475191200
2024-10-31UBS (Lux) Digital Health Equity SB USD1.52351.227450000000
2024-03-25SMDS Global AI Equity Mother1.52030.424449052000
2024-10-31Baillie Gifford WW Pstv Chg B USD Acc0.95580.56332823111456891.645
2024-11-27iShares Biotechnology ETF0.48360.0615142846914520.1018
2024-09-30Lazard Digital Health0.35062.17491035697600616.1561
2024-10-31ACATIS Datini Valueflex Fonds A0.33860.3435100000000
2024-03-31Mediolanum BB Global Impact L0.1880.24855538300
2024-10-31Desjardins Sustainable Positive Change F0.15880.522946912400
2024-09-30Vanguard Baillie GiffordGlbPstvImpStkInv0.15390.5065454435-25948-5.4015
2024-08-31Edinburgh Worldwide Ord0.14130.1118417365-502730-54.6389
2024-09-30Keystone Positive Change Investment Ord0.13680.490540392300
2024-10-31BlackRock Advantage Small Cap Core Instl0.1230.0246363294-1410-0.3866
2024-09-30SEB Artificial Intelligence D (USD)0.11520.380134026700
2024-11-27iShares Genomics Immnlgy & Hlthcr ETF0.10870.685732101700
2024-11-27iShares Healthcare Innov ETF USD Acc0.10280.083630368900
2024-03-31Baillie Gifford International Alp CIT C0.08310.441924548900
2024-09-30Federated Hermes Imp Opps Eq X USD Acc0.07630.897225489-11927-5.0237
Total 11.858310.516435025893-480266-1.4%

5.3. Insider Transactions

Insiders are holding 28.025% of the shares of Abcellera BiologicsĀ Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-26Andrew BoothBUY145006.85
2023-05-26Holdings Ltd. ThermopylaeBUY1530006.52
2022-12-16Holdings Ltd. ThermopylaeBUY8510210.1
2022-08-19Holdings Ltd. ThermopylaeBUY20000011.46
2022-06-13Holdings Ltd. ThermopylaeBUY549158.03
2022-06-06Holdings Ltd. ThermopylaeBUY645457.5
2022-05-16Veronique LecaultBUY2000006.34
2022-05-12Andrew BoothBUY850005.79
2022-05-12Holdings Ltd. ThermopylaeBUY14084686.41
2022-03-04John S MontalbanoBUY100008.54
2022-03-01John S MontalbanoBUY200009.05
2022-02-28Veronique LecaultBUY2307898.66
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,392,828
Total Liabilities314,734
Total Stockholder Equity1,078,094
 As reported
Total Liabilities 314,734
Total Stockholder Equity+ 1,078,094
Total Assets = 1,392,828

Assets

Total Assets1,392,828
Total Current Assets742,883
Long-term Assets649,945
Total Current Assets
Cash And Cash Equivalents 126,640
Short-term Investments 516,499
Net Receivables 63,236
Other Current Assets 36,508
Total Current Assets  (as reported)742,883
Total Current Assets  (calculated)742,883
+/-0
Long-term Assets
Property Plant Equipment 331,263
Goodwill 47,806
Intangible Assets 52,577
Long-term Assets Other 134,215
Long-term Assets  (as reported)649,945
Long-term Assets  (calculated)565,861
+/- 84,084

Liabilities & Shareholders' Equity

Total Current Liabilities79,568
Long-term Liabilities235,166
Total Stockholder Equity1,078,094
Total Current Liabilities
Short-term Debt 5,125
Accounts payable 34,795
Other Current Liabilities 34,070
Total Current Liabilities  (as reported)79,568
Total Current Liabilities  (calculated)73,990
+/- 5,578
Long-term Liabilities
Long-term Liabilities  (as reported)235,166
Long-term Liabilities  (calculated)0
+/- 235,166
Total Stockholder Equity
Common Stock772,832
Retained Earnings 151,140
Accumulated Other Comprehensive Income -1,232
Other Stockholders Equity 155,354
Total Stockholder Equity (as reported)1,078,094
Total Stockholder Equity (calculated)1,078,094
+/-0
Other
Cash and Short Term Investments 643,139
Common Stock Shares Outstanding 294,852
Current Deferred Revenue5,578
Liabilities and Stockholders Equity 1,392,828
Net Debt -55,241
Net Working Capital 663,315
Short Long Term Debt Total 71,399



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
23,488
0
192,211
142,385
1,005,536
1,128,523
1,151,856
1,172,732
1,318,569
1,592,289
1,593,784
1,552,409
1,540,907
1,497,919
1,537,166
1,512,190
1,488,094
1,463,096
1,412,481
1,392,828
1,392,8281,412,4811,463,0961,488,0941,512,1901,537,1661,497,9191,540,9071,552,4091,593,7841,592,2891,318,5691,172,7321,151,8561,128,5231,005,536142,385192,211023,488
   > Total Current Assets 
12,640
128,701
813,325
114,000
813,325
907,982
864,002
803,747
929,800
1,174,378
1,143,955
1,045,669
1,025,491
940,653
930,735
919,518
871,985
813,948
771,554
742,883
742,883771,554813,948871,985919,518930,735940,6531,025,4911,045,6691,143,9551,174,378929,800803,747864,002907,982813,325114,000813,325128,70112,640
       Cash And Cash Equivalents 
7,553
0
594,116
91,082
594,116
685,795
792,571
517,694
476,142
545,718
790,615
371,973
386,535
193,017
179,747
172,422
133,320
148,572
173,312
126,640
126,640173,312148,572133,320172,422179,747193,017386,535371,973790,615545,718476,142517,694792,571685,795594,11691,082594,11607,553
       Short-term Investments 
594,116
0
19,247
594,116
0
32,187
42,705
235,785
246,835
240,335
231,652
496,233
499,950
603,478
615,947
613,418
627,265
574,451
522,044
516,499
516,499522,044574,451627,265613,418615,947603,478499,950496,233231,652240,335246,835235,78542,70532,1870594,11619,2470594,116
       Net Receivables 
4,378
14,522
903
20,109
213,239
216,442
64,884
43,633
160,576
334,403
52,797
105,964
103,410
99,569
86,233
75,483
64,382
68,775
67,703
63,236
63,23667,70368,77564,38275,48386,23399,569103,410105,96452,797334,403160,57643,63364,884216,442213,23920,10990314,5224,378
       Other Current Assets 
-593,406
0
199,059
2,809
5,970
5,745
6,547
5,303
21,247
28,922
43,891
46,499
34,064
124,155
89,363
96,232
45,911
46,412
33,495
36,508
36,50833,49546,41245,91196,23289,363124,15534,06446,49943,89128,92221,2475,3036,5475,7455,9702,809199,0590-593,406
   > Long-term Assets 
10,848
0
-621,114
28,386
192,211
220,541
287,854
368,985
388,769
417,911
449,829
506,740
515,416
557,266
606,431
592,672
616,109
649,148
640,927
649,945
649,945640,927649,148616,109592,672606,431557,266515,416506,740449,829417,911388,769368,985287,854220,541192,21128,386-621,114010,848
       Property Plant Equipment 
8,480
11,616
17,923
14,278
17,923
34,618
87,479
91,584
111,616
122,049
149,178
200,602
217,255
233,187
259,640
277,209
287,696
306,081
318,882
331,263
331,263318,882306,081287,696277,209259,640233,187217,255200,602149,178122,049111,61691,58487,47934,61817,92314,27817,92311,6168,480
       Goodwill 
31,500
0
31,500
31,500
31,500
31,500
31,500
49,457
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80649,45731,50031,50031,50031,50031,500031,500
       Long Term Investments 
0
0
0
0
19,247
32,187
42,705
47,507
50,313
58,882
65,824
66,718
72,522
57,583
58,792
62,887
65,938
71,592
76,064
0
076,06471,59265,93862,88758,79257,58372,52266,71865,82458,88250,31347,50742,70532,18719,2470000
       Intangible Assets 
115,153
0
115,153
115,153
115,153
112,688
110,223
148,821
148,392
145,785
143,179
142,548
131,502
128,845
126,747
124,076
120,425
118,736
85,661
52,577
52,57785,661118,736120,425124,076126,747128,845131,502142,548143,179145,785148,392148,821110,223112,688115,153115,153115,1530115,153
       Long-term Assets Other 
585
0
-785,690
-151,792
8,388
9,548
15,947
31,616
23,234
43,389
43,842
49,066
41,031
89,845
113,446
80,694
94,244
54,433
57,814
134,215
134,21557,81454,43394,24480,694113,44689,84541,03149,06643,84243,38923,23431,61615,9479,5488,388-151,792-785,6900585
> Total Liabilities 
13,236
0
71,538
53,147
175,028
171,399
184,177
219,335
292,836
384,782
380,928
302,237
307,630
289,419
342,339
329,415
335,776
222,604
177,327
314,734
314,734177,327222,604335,776329,415342,339289,419307,630302,237380,928384,782292,836219,335184,177171,399175,02853,14771,538013,236
   > Total Current Liabilities 
7,895
18,269
103,490
20,104
103,490
88,395
69,758
49,549
120,676
213,418
221,140
106,052
118,320
89,591
118,905
110,239
119,013
104,883
70,380
79,568
79,56870,380104,883119,013110,239118,90589,591118,320106,052221,140213,418120,67649,54969,75888,395103,49020,104103,49018,2697,895
       Short-term Debt 
2,886
0
0
320
190
1,533
2,220
2,800
3,652
3,920
4,023
4,517
5,583
5,868
5,953
5,572
6,158
5,531
5,603
5,125
5,1255,6035,5316,1585,5725,9535,8685,5834,5174,0233,9203,6522,8002,2201,533190320002,886
       Short Long Term Debt 
2,467
0
0
320
190
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000190320002,467
       Accounts payable 
1,643
2,522
2,522
36,152
20,005
13,287
18,276
8,908
32,017
10,352
10,313
9,319
14,828
17,569
21,025
17,432
25,509
26,907
26,585
34,795
34,79526,58526,90725,50917,43221,02517,56914,8289,31910,31310,35232,0178,90818,27613,28720,00536,1522,5222,5221,643
       Other Current Liabilities 
129
14,948
96,901
-23,284
76,706
62,269
38,694
27,724
77,471
184,906
196,411
79,116
70,012
47,762
76,864
63,374
68,388
61,880
31,791
34,070
34,07031,79161,88068,38863,37476,86447,76270,01279,116196,411184,90677,47127,72438,69462,26976,706-23,28496,90114,948129
   > Long-term Liabilities 
5,341
0
-31,952
33,043
71,538
83,004
114,419
169,786
172,160
171,364
159,788
196,185
189,310
199,828
223,434
219,176
216,763
117,721
106,947
235,166
235,166106,947117,721216,763219,176223,434199,828189,310196,185159,788171,364172,160169,786114,41983,00471,53833,043-31,95205,341
       Long term Debt 
1,363
0
0
1,939
2,198
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,1981,939001,363
       Capital Lease Obligations 
3,061
0
0
3,066
3,715
18,506
31,020
30,064
36,413
40,276
36,782
76,108
82,258
83,133
84,032
80,757
77,380
73,610
72,054
0
072,05473,61077,38080,75784,03283,13382,25876,10836,78240,27636,41330,06431,02018,5063,7153,066003,061
       Other Liabilities 
1,336
26,686
26,686
28,038
65,625
65,131
83,399
142,522
134,014
135,008
127,029
124,594
112,635
0
145,355
143,991
0
0
0
0
0000143,991145,3550112,635124,594127,029135,008134,014142,52283,39965,13165,62528,03826,68626,6861,336
       Long-term Liabilities Other 
0
0
0
4,320
4,422
931
1,657
133,589
134,790
134,560
125,172
162,042
3,086
166,402
190,256
5,051
5,906
5,735
6,348
0
06,3485,7355,9065,051190,256166,4023,086162,042125,172134,560134,790133,5891,6579314,4224,320000
       Deferred Long Term Liability 
0
0
0
0
0
26,992
25,510
36,197
37,370
36,804
34,616
34,143
33,178
33,426
33,178
0
0
0
0
0
0000033,17833,42633,17834,14334,61636,80437,37036,19725,51026,99200000
> Total Stockholder Equity
10,252
0
830,508
89,238
830,508
957,124
967,679
953,397
1,025,733
1,207,507
1,212,856
1,250,172
1,233,277
1,208,500
1,194,827
1,182,775
1,152,318
1,129,913
1,110,968
1,078,094
1,078,0941,110,9681,129,9131,152,3181,182,7751,194,8271,208,5001,233,2771,250,1721,212,8561,207,5071,025,733953,397967,679957,124830,50889,238830,508010,252
   Common Stock
5,122
5,373
5,373
88,582
710,387
711,139
714,758
718,088
722,430
725,755
726,825
730,427
734,365
742,816
744,756
747,914
753,199
764,562
769,966
772,832
772,832769,966764,562753,199747,914744,756742,816734,365730,427726,825725,755722,430718,088714,758711,139710,38788,5825,3735,3735,122
   Retained Earnings Total Equity
0
0
0
0
0
231,423
229,100
207,720
267,666
436,239
429,454
456,078
426,185
386,075
355,547
0
0
0
0
0
00000355,547386,075426,185456,078429,454436,239267,666207,720229,100231,42300000
   Accumulated Other Comprehensive Income 
-3,157
0
0
0
0
0
2,152
644
280
787
576
-717
-1,391
-2,021
-1,899
-1,460
-1,720
-1,816
-2,073
-1,232
-1,232-2,073-1,816-1,720-1,460-1,899-2,021-1,391-7175767872806442,15200000-3,157
   Capital Surplus 
0
0
0
0
0
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
0
0
0
0
0
0000096,42381,63074,11864,38456,00144,72635,35726,94521,66914,56200000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
5,457
0
830,508
3,453
5,919
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
109,384
121,052
127,990
140,828
155,354
155,354140,828127,990121,052109,38496,42381,63074,11864,38456,00144,72635,35726,94521,66914,5625,9193,453830,50805,457



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue38,025
Cost of Revenue-30,894
Gross Profit38,0257,131
 
Operating Income (+$)
Gross Profit38,025
Operating Expense-275,232
Operating Income-237,207-237,207
 
Operating Expense (+$)
Research Development175,658
Selling General Administrative60,999
Selling And Marketing Expenses14,180
Operating Expense275,232250,837
 
Net Interest Income (+$)
Interest Income42,247
Interest Expense-0
Other Finance Cost-0
Net Interest Income42,247
 
Pretax Income (+$)
Operating Income-237,207
Net Interest Income42,247
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-174,029-300,385
EBIT - interestExpense = -223,052
-174,029
-146,398
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-223,052-174,029
Earnings Before Interest and Taxes (EBITDA)-192,158
 
After tax Income (+$)
Income Before Tax-174,029
Tax Provision--27,631
Net Income From Continuing Ops-146,398-146,398
Net Income-146,398
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses275,232
Total Other Income/Expenses Net63,178-42,247
 

Technical Analysis of Abcellera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abcellera. The general trend of Abcellera is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abcellera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abcellera BiologicsĀ Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.18 < 3.435 < 3.58.

The bearish price targets are: 2.57 > 2.5 > 2.43.

Tweet this
Abcellera BiologicsĀ Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abcellera BiologicsĀ Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abcellera BiologicsĀ Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abcellera BiologicsĀ Inc. The current macd is 0.04561941.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abcellera price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Abcellera. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Abcellera price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Abcellera BiologicsĀ Inc Daily Moving Average Convergence/Divergence (MACD) ChartAbcellera BiologicsĀ Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abcellera BiologicsĀ Inc. The current adx is 19.60.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Abcellera shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Abcellera BiologicsĀ Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abcellera BiologicsĀ Inc. The current sar is 2.68516845.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Abcellera BiologicsĀ Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abcellera BiologicsĀ Inc. The current rsi is 49.11. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Abcellera BiologicsĀ Inc Daily Relative Strength Index (RSI) ChartAbcellera BiologicsĀ Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abcellera BiologicsĀ Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Abcellera price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Abcellera BiologicsĀ Inc Daily Stochastic Oscillator ChartAbcellera BiologicsĀ Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abcellera BiologicsĀ Inc. The current cci is -5.04023132.

Abcellera BiologicsĀ Inc Daily Commodity Channel Index (CCI) ChartAbcellera BiologicsĀ Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abcellera BiologicsĀ Inc. The current cmo is -7.67047044.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Abcellera BiologicsĀ Inc Daily Chande Momentum Oscillator (CMO) ChartAbcellera BiologicsĀ Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abcellera BiologicsĀ Inc. The current willr is -54.80769231.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Abcellera is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Abcellera BiologicsĀ Inc Daily Williams %R ChartAbcellera BiologicsĀ Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Abcellera BiologicsĀ Inc.

Abcellera BiologicsĀ Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abcellera BiologicsĀ Inc. The current atr is 0.16107628.

Abcellera BiologicsĀ Inc Daily Average True Range (ATR) ChartAbcellera BiologicsĀ Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abcellera BiologicsĀ Inc. The current obv is -32,438,977.

Abcellera BiologicsĀ Inc Daily On-Balance Volume (OBV) ChartAbcellera BiologicsĀ Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abcellera BiologicsĀ Inc. The current mfi is 57.32.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Abcellera BiologicsĀ Inc Daily Money Flow Index (MFI) ChartAbcellera BiologicsĀ Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abcellera BiologicsĀ Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Abcellera BiologicsĀ Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abcellera BiologicsĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.110
Ma 20Greater thanMa 502.840
Ma 50Greater thanMa 1002.736
Ma 100Greater thanMa 2002.741
OpenGreater thanClose2.850
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Abcellera with someone you think should read this too:
  • Are you bullish or bearish on Abcellera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abcellera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abcellera BiologicsĀ Inc

I send you an email if I find something interesting about Abcellera BiologicsĀ Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Abcellera BiologicsĀ Inc.

Receive notifications about Abcellera BiologicsĀ Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.